Anti-human CXCR4 Recombinant Monoclonal Antibody (HM0088)
Price range: $230.00 through $720.00
Anti-human CXCR4 Recombinant Monoclonal Antibody (HM0088) is a high-affinity recombinant monoclonal antibody generated by phage-display selection from a mouse-derived antibody library followed by structure-guided affinity optimization. The antibody was validated by ELISA against recombinant epitope-Fc fusion antigen and by Western blot detection of endogenous CXCR4 protein.
Also known as: hCXCR4, CXCR4, CD184, Fusin, and SDF-1 receptor.
For research use only. Not for diagnostic or therapeutic applications.
Product Information
| Property | Description |
|---|---|
| Product Name | Anti-human CXCR4 Recombinant Monoclonal Antibody |
| Antibody ID | HM0088 |
| Target Protein | C-X-C chemokine receptor type 4 |
| Target Protein Short Name | CXCR4 |
| UniProt Accession | P61073-1 |
| Molecular Weight | Human: 39.7 kDa |
| Antibody Type | Recombinant monoclonal antibody |
| Host Species | Mouse |
| Recombinant Format | Full-length mouse IgG1 |
| Isotype | Mouse IgG1 |
| Species Reactivity | Human |
| Tested Applications | WB |
| Recommended Dilution for WB | 1:500–1:5000 |
| Antigen | Recombinant epitope-Fc fusion protein |
| Epitope Sequence | GISIYTSDNYTEEMGSGDYDSM |
| Expression System | HEK293 cells |
| Purification | Protein G affinity chromatography |
| Conjugate | Unconjugated |
| Concentration | 0.1 mg/mL |
| Storage Buffer | 0.1 M Tris, 0.05 M Glycine, 0.07 M NaCl, 2 g/L BSA, 50% glycerol, pH 7 |
| Storage Condition | Store at -20°C |
| Research Use | For research use only. Not for diagnostic or therapeutic applications |
Product Background
CXCR4 (C-X-C chemokine receptor type 4) is a G protein-coupled chemokine receptor that binds CXCL12/SDF-1 and regulates immune cell trafficking, stem cell homing, hematopoiesis, cancer metastasis, angiogenesis, and inflammatory signaling pathways.
CXCR4 is widely studied in immunology, cancer biology, stem cell biology, HIV research, hematopoiesis, chemokine signaling, GPCR biology, and receptor pharmacology.
Antibody Development
HM0088 was generated by phage-display selection using a mouse-derived antibody library. Recombinant epitope-Fc fusion protein containing the CXCR4 epitope sequence was used as the selection antigen. Following identification of the initial antibody candidate, structure-guided affinity optimization was performed to improve binding affinity and specificity.
The optimized antibody was reconstructed as a full-length mouse IgG1 recombinant antibody and expressed in HEK293 cells.
Binding and specificity were evaluated by:
- ELISA using recombinant epitope-Fc fusion antigen
- Western blot detection of endogenous full-length CXCR4 protein
Validation Data
ELISA Validation
ELISA demonstrated specific binding to recombinant epitope-Fc fusion antigen, while minimal binding was observed against Fc control protein.
Validation conditions:
- Well 1: Fc control protein
- Well 2: Epitope-Fc fusion protein
- Detection substrate: TMB
Note:
ELISA validation confirms binding to the epitope-Fc fusion antigen. Full-length CXCR4 protein binding in solution has not been tested by ELISA.
Western Blot Validation – Endogenous Full-Length Protein
Western blot analysis detected endogenous full-length CXCR4 protein under reducing conditions.
Validated samples:
- 293T cells
- HeLa cells
- HepG2 cells
Detection condition:
- Standard reducing Western blot
- HRP-conjugated anti-mouse secondary antibody
Observed bands:
- Observed bands may represent receptor oligomers, glycosylated receptor species, receptor processing intermediates, or post-translationally modified receptor forms commonly observed for GPCR proteins under reducing Western blot conditions.
| Size | 20 ul, 100 ul |
|---|
Related products
